Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Business Wire May 16, 2014

Exosomes Common Link in Cancer Drug Development

Accesswire May 15, 2014

In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

Business Wire May 14, 2014

Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study

Business Wire May 14, 2014

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma

Business Wire May 14, 2014

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b Non-Small Cell Lung Cancer Trials

Business Wire May 14, 2014

Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab

Business Wire May 14, 2014

Bristol-Myers Squibb to Present at UBS Global Healthcare Conference

Business Wire May 12, 2014

Bristol-Myers Squibb Announces Retirement of Brian Daniels

Business Wire May 6, 2014

Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology with Broad Set of New Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 5, 2014

Are Exosomes the Next PD-1 in Cancer Research?

Accesswire April 30, 2014

Bristol-Myers Squibb Reports First Quarter 2014 Financial Results

Business Wire April 29, 2014

Bristol-Myers Squibb Acquires iPierian, Inc.

Business Wire April 29, 2014

Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List

Business Wire April 24, 2014

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Business Wire April 22, 2014

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Business Wire April 14, 2014

Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients

Canada NewsWire April 10, 2014

Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients

Business Wire April 10, 2014

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure(TM) Virology Research Programme

PR Newswire April 8, 2014

Gilead's (GILD) Blockbuster Hepatitis-C Drug Sovaldi Steps Up Race

Equities.com April 7, 2014